Analyst Reco. ACADIA Pharmaceuticals Inc.

Equities

ACAD

US0042251084

Real-time Estimate Cboe BZX Other stock markets 02:45:47 2024-04-26 pm EDT			5-day change	1st Jan Change
16.59 ^USD	+1.72%		-1.81%	-47.25%

Apr. 23	Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada	MT
Apr. 22	Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Adjusts Price Target on ACADIA Pharmaceuticals to $25 From $29, Maintains Overweight Rating	Mar. 25	MT
UBS Adjusts ACADIA Pharmaceuticals Price Target to $33 From $35, Maintains Buy Rating	Mar. 13	MT
Morgan Stanley Cuts Price Target on ACADIA Pharmaceuticals to $30 From $40 After Failed Study of Pimavanserin in Negative Symptoms of Schizophrenia; Overweight Kept	Mar. 13	MT
Deutsche Bank Adjusts ACADIA Pharmaceuticals Price Target to $22 From $24, Maintains Hold Rating	Mar. 12	MT
Cantor Fitzgerald Adjusts Price Target on ACADIA Pharmaceuticals to $37 From $42, Maintains Overweight Rating	Mar. 12	MT
Baird Adjusts Price Target on ACADIA Pharmaceuticals to $31 From $40, Maintains Outperform Rating	Mar. 12	MT
Needham Lowers Price Target on ACADIA Pharmaceuticals to $32 From $36, Keeps Buy Rating	Mar. 12	MT
Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $19 From $25, Maintains Perform Rating	Mar. 12	MT
Canaccord Genuity Adjusts Price Target on ACADIA Pharmaceuticals to $33 From $40, Keeps Buy Rating	Mar. 12	MT
JMP Securities Cuts ACADIA Pharmaceuticals Price Target to $39 From $44, Maintains Market Outperform Rating	Mar. 12	MT
RBC Cuts Price Target on ACADIA Pharmaceuticals to $30 From $35 After Phase 3 Trial of Pimavanserin Fails to Reach Primary Endpoint; Outperform Kept	Mar. 12	MT
Mizuho Securities Downgrades ACADIA Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $25 From $39	Mar. 12	MT
JPMorgan Cuts Price Target on ACADIA Pharmaceuticals to $29 From $32, Maintains Overweight Rating	Mar. 01	MT
Deutsche Bank Trims ACADIA Pharmaceuticals Price Target to $24 From $25, Maintains Hold Rating	Feb. 28	MT
Needham Trims Price Target on ACADIA Pharmaceuticals to $36 From $37, Maintains Buy Rating	Feb. 28	MT
Mizuho Securities Adjusts Price Target on ACADIA Pharmaceuticals to $39 From $40, Maintains Buy Rating	Feb. 28	MT
RBC Trims Price Target on ACADIA Pharmaceuticals to $35 From $36, Keeps Outperform Rating	Feb. 28	MT
Baird Initiates ACADIA Pharmaceuticals With Outperform Rating, Price Target is $40	Jan. 30	MT
Needham Upgrades ACADIA Pharmaceuticals to Buy From Hold, Price Target is $37	Jan. 24	MT
RBC Boosts Price Target on ACADIA Pharmaceuticals to $36 From $33, Keeps Outperform Rating	Jan. 03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. ACADIA Pharmaceuticals Inc.

Equities

ACAD

US0042251084

Analyst Reco.

Filters